Komori
Otsuka Holdings (4578) · InitiativeAdvancedLatest Share Issuance and Disposal (2026-04-24): "Achieved"

Issuance of Stock Acquisition Rights to Directors

First written in FY2016-Q2. 8 of 13 entries say "Advanced", first in FY2019-Q2. Latest entry: 2026-04-24.

13entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016-Q2 – FY2016AdvancedFY2019-Q2 – FY2022AdvancedFY2024 – 2026-04-242016: 120162017: 120172018: 020182019: 220192020: 120202021: 120212022: 120222023: 120232024: 120242025: 120252026: 3
Same theme, other companies
Medium- to Long-Term Incentives Through Equity Compensation Plans for Directors and EmployeesA theme 669 companies write about · 0 as a headwind · 692 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 192 companies compared. The sentences above are computed from all 192.Comparing 200 of the theme's 692 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025AdvancedAnnual report

    「Grant date 25 April 2025 Number granted 88,340 shares Fair value at grant date ¥7,981」

    The company granted 88,340 shares on 25 April 2025 under restricted stock compensation linked to the performance indicators and other targets of the Fourth Medium-Term Management Plan.
  2. FY2024AdvancedAnnual report

    「The company has introduced a share-based compensation plan that reflects achievement of the performance indicators and other targets under the Fourth Medium-Term Management Plan, covering fiscal years 2024 through 2028.」

    The company implemented restricted stock compensation linked to the Fourth Medium-Term Management Plan and established EPS, TSR, operating cash flow before R&D investment, ROIC and FTSE as performance indicators. In April 2024, it granted 363,900 shares.
  3. FY2023ReframedAnnual report

    「The company has introduced a share-based compensation plan that reflects achievement of the performance indicators and other targets under the Fourth Medium-Term Management Plan, covering fiscal years 2024 through 2028.」

    The company moved from the restricted stock compensation plan linked to the Third Medium-Term Management Plan to a plan that evaluates EPS, TSR, operating cash flow before R&D investment, ROIC and FTSE under the Fourth Medium-Term Management Plan.
  4. FY2022AdvancedAnnual report

    「Grant date 28 April 2022 Number granted 241,920 shares Fair value at grant date ¥4,271」

    The company granted 241,920 shares as restricted stock compensation on 28 April 2022 and continues to operate a plan linked to performance achievement under the Third Medium-Term Management Plan.
  5. FY2021AdvancedAnnual report

    「Grant date 28 April 2021 Number granted 71,320 shares Fair value at grant date ¥4,804」

    The company granted 71,320 shares as restricted stock compensation on 28 April 2021 and continues to operate a plan linked to achievement under the Third Medium-Term Management Plan and related performance targets.
  6. FY2020AdvancedAnnual report

    「Grant date 24 April 2020 Number granted 80,880 shares Fair value at grant date ¥3,785」

    The company granted 80,880 shares as restricted stock compensation on 24 April 2020 and continues to operate a plan linked to achievement under the Third Medium-Term Management Plan and medium- to long-term increases in corporate value.
  7. FY2019AdvancedAnnual report

    「From the current consolidated fiscal year, the Group introduced a restricted stock compensation plan for company directors, excluding outside directors, and certain directors of its subsidiaries. The plan is intended to provide incentives to achieve the medium-term management plan and, in turn, achieve sustainable medium- to long-term growth in performance and corporate value, while promoting greater value sharing with shareholders.」

    The company granted 340,120 restricted shares as compensation on 20 May 2019, and the previous stock option plan ended upon expiration of the applicable period.
  8. FY2019-Q2AdvancedAnnual report

    「Treasury shares decreased by 340,120 shares through the disposal of treasury shares conducted on 20 May 2019 as restricted stock compensation.」

    As part of the expansion of the share-based compensation system from the previous stock acquisition rights to restricted stock compensation, the company disposed of 340,120 treasury shares on 20 May 2019.
  9. FY2018ReframedAnnual report

    「For share-based compensation, the annual limit for compensation to grant restricted shares as an incentive plan aimed at sustainable medium- to long-term growth in performance and corporate value was approved at ¥1,000 million at the annual general meeting of shareholders held on 28 March 2019, separately from the annual limit of ¥1,500 million stated above.」

    The company stated its policy of introducing a medium- to long-term incentive system based on restricted shares in addition to the existing stock acquisition rights for directors. The system is expected to be linked to performance targets covering multiple fiscal years under the Third Medium-Term Management Plan.
  10. FY2016RestatedAnnual report

    「2016 Fifth Stock Option Company directors, excluding outside directors; directors of subsidiaries who do not concurrently serve as company directors 851,400 shares」

    The company continues to disclose the Fifth Series of Stock Acquisition Rights for directors, covering 851,400 shares and an exercise period from March 2019 to February 2021.
  11. FY2016-Q2First statedAnnual report

    「Fifth Series of Stock Acquisition Rights (approved by the Board of Directors on 13 May 2016; issued on 31 May 2016)」

    Stock acquisition rights covering 851,400 shares were issued to the company's directors and directors of its subsidiaries. The exercise period runs from 1 March 2019 to 28 February 2021.
Moved together

"Pipeline Progress in Clinical Development, Regulatory Approval and Commercialization" moved the same way as this thread, in the same document, in 7 of its 13 moves.

776654★123456
  1. ★This thread
  2. 1Pipeline Progress in Clinical Development, Regulatory Approval and Commercialization7×
  3. 2Expansion of Overseas Sales of Pharmaceutical and Health-Related Products7×
  4. 3Investment Plan for Research and Production Facilities6×
  5. 4Impairment Risk from Changes in the Business Environment and Revisions to Business Plans6×
  6. 5Research and development of functional foods and beverages leveraging know-how from healthcare-related businesses5×
  7. 6Sustainable growth driven by 3 global products and 3 next-generation products4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Otsuka Holdings's next results are scheduled for 2026-10-30. Read the earnings preview It last moved in the Share Issuance and Disposal of 2026-04-24: "Achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Issuance of Stock Acquisition Rights to Directors | Otsuka Holdings Co.,Ltd. (4578) | Komori